Analysts estimates are all based on pre-FDA approval, and they are correct, the market for their drug is limited. Now with the expanded label they have access to 650,000 patients who, today, are treated by IV injections, which are time consuming and expensive.
KERX is a pill that you take at home, and it works better. Doctors are going to switch in droves.
Analysts are going to have to revise their estimates of this company, and you’ll see the fair market value will explode.
News 
Market Data 
Discover 
